Literature DB >> 21835703

Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment.

Winnie Ridderberg1, Karen E M Bendstrup, Hanne V Olesen, Søren Jensen-Fangel, Niels Nørskov-Lauritsen.   

Abstract

BACKGROUND: An increased incidence of Achromobacter xylosoxidans infections has been observed at the Cystic Fibrosis Centre at Aarhus University Hospital, as the proportion of patients colonised with A. xylosoxidans increased from 6 to 10% from 2005 to 2009.
METHODS: Pulsed field gel electrophoresis (PFGE) was used to type isolates of A. xylosoxidans.
RESULTS: Four patients infected for 2-7 years were part of a larger epidemic spread involving both Danish CF centres, while 11 patients carried strains with unique genotypes. Longitudinal analysis of isolates from ten patients with multiple preserved isolates showed that each patient persistently carried isolates of a single genotype. Following lung transplantation, two patients showed re-colonisation of the lung grafts with the pre-transplant A. xylosoxidans strain.
CONCLUSIONS: A. xylosoxidans has been transmitted between patients from our clinic, but the recent increase in incidence is not caused by cross infections.
Copyright © 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21835703     DOI: 10.1016/j.jcf.2011.07.004

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  31 in total

1.  Genetic and biochemical characterization of a novel metallo-β-lactamase, TMB-1, from an Achromobacter xylosoxidans strain isolated in Tripoli, Libya.

Authors:  Allaaeddin El Salabi; Pardha Saradhi Borra; Mark A Toleman; Ørjan Samuelsen; Timothy R Walsh
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

2.  Chronic Airway Colonization by Achromobacter xylosoxidans in Cystic Fibrosis Patients Is Not Sustained by Their Domestic Environment.

Authors:  Chloé Dupont; Estelle Jumas-Bilak; Clara Doisy; Fabien Aujoulat; Raphaël Chiron; Hélène Marchandin
Journal:  Appl Environ Microbiol       Date:  2018-11-15       Impact factor: 4.792

3.  Prevalence and Outcomes of Achromobacter Species Infections in Adults with Cystic Fibrosis: a North American Cohort Study.

Authors:  B D Edwards; J Greysson-Wong; R Somayaji; B Waddell; F J Whelan; D G Storey; H R Rabin; M G Surette; M D Parkins
Journal:  J Clin Microbiol       Date:  2017-04-26       Impact factor: 5.948

4.  Child toy safety: An interdisciplinary approach to unravel the microbiological hazard posed by soap bubbles.

Authors:  Irene Amoruso; Chiara Bertoncello; Gianumberto Caravello; Valerio Giaccone; Tatjana Baldovin
Journal:  J Public Health Policy       Date:  2015-10-01       Impact factor: 2.222

5.  Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis.

Authors:  Elizabeth L Salsgiver; Aliza K Fink; Emily A Knapp; John J LiPuma; Kenneth N Olivier; Bruce C Marshall; Lisa Saiman
Journal:  Chest       Date:  2016-01-12       Impact factor: 9.410

6.  Characterization of Achromobacter Species in Cystic Fibrosis Patients: Comparison of bla(OXA-114) PCR Amplification, Multilocus Sequence Typing, and Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry.

Authors:  Elenice R A Rodrigues; Alex G Ferreira; Robson S Leão; Cassiana C F Leite; Ana Paula Carvalho-Assef; Rodolpho M Albano; Elizabeth A Marques
Journal:  J Clin Microbiol       Date:  2015-12       Impact factor: 5.948

7.  Detection of Achromobacter xylosoxidans in hospital, domestic, and outdoor environmental samples and comparison with human clinical isolates.

Authors:  Lucie Amoureux; Julien Bador; Sakina Fardeheb; Cédric Mabille; Charlyne Couchot; Clémence Massip; Anne-Lise Salignon; Guillaume Berlie; Véronique Varin; Catherine Neuwirth
Journal:  Appl Environ Microbiol       Date:  2013-09-13       Impact factor: 4.792

8.  OXA-258 from Achromobacter ruhlandii: a species-specific marker.

Authors:  Mariana Papalia; Marisa Almuzara; Daniela Cejas; German Traglia; Maria Soledad Ramírez; Laura Galanternik; Carlos Vay; Gabriel Gutkind; Marcela Radice
Journal:  J Clin Microbiol       Date:  2013-03-06       Impact factor: 5.948

Review 9.  Achromobacter Infections and Treatment Options.

Authors:  Burcu Isler; Timothy J Kidd; Adam G Stewart; Patrick Harris; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

10.  Innate aminoglycoside resistance of Achromobacter xylosoxidans is due to AxyXY-OprZ, an RND-type multidrug efflux pump.

Authors:  Julien Bador; Lucie Amoureux; Emmanuel Blanc; Catherine Neuwirth
Journal:  Antimicrob Agents Chemother       Date:  2012-10-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.